YSB Valuation
Is 9885 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 9885 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 9885 (HK$8.08) is trading below our estimate of fair value (HK$154.75)
Significantly Below Fair Value: 9885 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 9885?
Other financial metrics that can be useful for relative valuation.
What is 9885's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | CN¥4.81b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 0.2x |
Enterprise Value/EBITDA | -189.7x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 9885's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 1.3x | ||
3390 Tycoon Group Holdings | 2.7x | n/a | HK$3.2b |
1931 IVD Medical Holding | 0.8x | n/a | HK$2.7b |
1345 Shanghai Pioneer Holding | 1.3x | n/a | HK$2.2b |
9955 ClouDr Group | 0.5x | 19.2% | HK$1.8b |
9885 YSB | 0.3x | n/a | HK$5.2b |
Price-To-Sales vs Peers: 9885 is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (1.3x).
Price to Earnings Ratio vs Industry
How does 9885's PE Ratio compare vs other companies in the HK Healthcare Industry?
Price-To-Sales vs Industry: 9885 is good value based on its Price-To-Sales Ratio (0.3x) compared to the Hong Kong Healthcare industry average (1x).
Price to Sales Ratio vs Fair Ratio
What is 9885's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 0.3x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 9885's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.